

# Theodosia A Kalfa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2598966/publications.pdf>

Version: 2024-02-01

117  
papers

3,308  
citations

172457

29  
h-index

161849

54  
g-index

119  
all docs

119  
docs citations

119  
times ranked

5028  
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered erythropoiesis in newborns with congenital heart disease. <i>Pediatric Research</i> , 2022, 91, 606-611.	2.3	2
2	Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 380, 210-219.	2.5	18
3	M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recycling. <i>Scientific Reports</i> , 2022, 12, 1235.	3.3	2
4	Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT4202), an Allosteric Activator of Pyruvate Kinase, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 654-665.	1.6	11
5	eP420: Clinical utility of a 38-gene NGS panel in diagnosing patients with hemolytic anemia: A retrospective review of 435 cases. <i>Genetics in Medicine</i> , 2022, 24, S263.	2.4	0
6	Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening. <i>FASEB Journal</i> , 2022, 36, e22360.	0.5	0
7	Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis. <i>American Journal of Hematology</i> , 2022, 97, 1384-1385.	4.1	0
8	Autism-associated chromatin remodeler CHD8 regulates erythroblast cytokinesis and fine-tunes the balance of Rho GTPase signaling. <i>Cell Reports</i> , 2022, 40, 111072.	6.4	2
9	Rasa3 regulates stage-specific cell cycle progression in murine erythropoiesis. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102524.	1.4	2
10	ER-to-Golgi transport and SEC23-dependent COPII vesicles regulate T cell alloimmunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	6
11	Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). <i>Blood Cells, Molecules, and Diseases</i> , 2021, 87, 102534.	1.4	3
12	Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29008.	1.5	5
13	Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. <i>Frontiers in Physiology</i> , 2021, 12, 636609.	2.8	7
14	Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients. <i>Scientific Reports</i> , 2021, 11, 7909.	3.3	6
15	Base editing of haematopoietic stem cells rescues sickle cell disease in mice. <i>Nature</i> , 2021, 595, 295-302.	27.8	175
16	Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pan-cellular expression of fetal haemoglobin in children with sickle cell anaemia. <i>British Journal of Haematology</i> , 2021, 194, 617-625.	2.5	16
17	Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 90, 102576.	1.4	2
18	Autoimmune Hemolytic Anemia in the Pediatric Setting. <i>Journal of Clinical Medicine</i> , 2021, 10, 216.	2.4	22

#	ARTICLE	IF	CITATIONS
19	Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice By Altering the Bone Marrow Erythropoietic Niche. <i>Blood</i> , 2021, 138, 1989-1989.	1.4	0
20	Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks. <i>Blood</i> , 2021, 138, 9-9.	1.4	5
21	Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease. <i>Blood</i> , 2021, 138, 4162-4162.	1.4	2
22	Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study. <i>Blood</i> , 2021, 138, 8-8.	1.4	3
23	SERF1 Is Required for G-CSF Resistance of Start-Codon Mutant ELANE Granulocytic Precursors. <i>Blood</i> , 2021, 138, 433-433.	1.4	0
24	Diagnosis and clinical management of red cell membrane disorders. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 331-340.	2.5	7
25	VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. <i>American Journal of Human Genetics</i> , 2020, 107, 1149-1156.	6.2	20
26	Red cell membrane disorders: structure meets function. <i>Blood</i> , 2020, 136, 1250-1261.	1.4	47
27	How I approach hereditary hemolytic anemia and splenectomy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28337.	1.5	8
28	Long-term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28290.	1.5	5
29	Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease. <i>British Journal of Haematology</i> , 2020, 190, 599-609.	2.5	46
30	A painless erythematous swelling of the external ear as a manifestation of Lyme disease: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 48.	0.8	2
31	FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. <i>Blood</i> , 2020, 136, 19-20.	1.4	12
32	Angiotensin Signaling Is Essential for Stress Erythropoiesis but Results in Retention of Dysfunctional Mitochondria in Erythrocytes That Generate Excessive Reactive Oxygen Species. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
33	Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
34	Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use. <i>Blood</i> , 2020, 136, 23-24.	1.4	1
35	Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience. <i>Blood</i> , 2020, 136, 34-34.	1.4	0
36	Rare Hereditary Hemolytic Anemias. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 373-392.	2.2	22

#	ARTICLE	IF	CITATIONS
37	The Spectrum of SPTA1-Associated Hereditary Spherocytosis. <i>Frontiers in Physiology</i> , 2019, 10, 815.	2.8	32
38	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. <i>American Journal of Hematology</i> , 2019, 94, 871-879.	4.1	51
39	Hereditary elliptocytosis-associated alpha-spectrin mutation p.L155dup as a modifier of sickle cell disease severity. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27531.	1.5	2
40	Acquired Hemolytic Anemias. , 2019, , 67-79.		0
41	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2019, 94, 149-161.	4.1	55
42	Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. <i>Blood</i> , 2019, 134, 616-616.	1.4	6
43	VPS4A mutations Cause a Syndrome with Dyserythropoiesis, Hemolytic Anemia, and Neurodevelopmental Delay. <i>Blood</i> , 2019, 134, 339-339.	1.4	0
44	Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR). <i>Blood</i> , 2019, 134, 3521-3521.	1.4	0
45	Congenital dyserythropoietic anaemia type I diagnosed in a young adult with a history of splenectomy in childhood for presumed haemolytic anaemia. <i>British Journal of Haematology</i> , 2018, 182, 10-10.	2.5	6
46	Hereditary xerocytosis: Diagnostic considerations. <i>American Journal of Hematology</i> , 2018, 93, E67-E69.	4.1	7
47	Alu element insertion inPKLRgene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients. <i>Human Mutation</i> , 2018, 39, 389-393.	2.5	4
48	Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models. <i>Haematologica</i> , 2018, 103, 40-50.	3.5	30
49	Analysis of Erythropoiesis Using Imaging Flow Cytometry. <i>Methods in Molecular Biology</i> , 2018, 1698, 175-192.	0.9	7
50	Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia. <i>Blood</i> , 2018, 132, 507-507.	1.4	1
51	Evaluation of Phenotype-Genotype Correlation in Two Common PIEZO1 Mutations p.R2456H and p.L2495_E2495dup. <i>Blood</i> , 2018, 132, 1040-1040.	1.4	1
52	Gene Therapy for Sickle Cell Anemia Using a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant Shows Promising Correction of the Disease Phenotype. <i>Blood</i> , 2018, 132, 1021-1021.	1.4	23
53	Peroxiredoxin II (PRDX2) Is a Novel Candidate Gene for Congenital Dyserythropoietic Anemia. <i>Blood</i> , 2018, 132, 3605-3605.	1.4	4
54	Rac GTPase. , 2018, , 4408-4414.		0

#	ARTICLE	IF	CITATIONS
55	The Erythro-Myeloblastic Island (EMBI): A Hematopoietic Niche Balancing Erythropoiesis and Myelopoiesis. <i>Blood</i> , 2018, 132, 842-842.	1.4	0
56	Novel mechanisms of PIEZO1 dysfunction in hereditary xerocytosis. <i>Blood</i> , 2017, 130, 1845-1856.	1.4	101
57	Unraveling Macrophage Heterogeneity in Erythroblastic Islands. <i>Frontiers in Immunology</i> , 2017, 8, 1140.	4.8	73
58	Rac GTPase. , 2017, , 1-7.		0
59	<i>VPS4A</i> : A Novel Candidate Gene for Congenital Dyserythropoietic Anemia. <i>Blood</i> , 2017, 130, 923-923.	1.4	1
60	RGL2 Deficiency Impairs Human Erythropoiesis By Altering Terminal Erythroid Differentiation and Apoptosis. <i>Blood</i> , 2017, 130, 8-8.	1.4	0
61	Warm antibody autoimmune hemolytic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 690-697.	2.5	83
62	Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab. <i>British Journal of Haematology</i> , 2016, 175, 744-747.	2.5	14
63	Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 61, 4-9.	1.4	60
64	Effects of hydroxyurea treatment for patients with hemoglobin <i>SC</i> disease. <i>American Journal of Hematology</i> , 2016, 91, 238-242.	4.1	54
65	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWITCH): a multicentre, open-label, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2016, 387, 661-670.	13.7	375
66	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. <i>Journal of Pediatric Surgery</i> , 2016, 51, 122-127.	1.6	39
67	Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the <i>TWITCH</i> trial. <i>British Journal of Haematology</i> , 2016, 172, 122-130.	2.5	47
68	Iron Unloading By Therapeutic Phlebotomy in Previously Transfused Children with Sickle Cell Anemia: The Twitch Experience. <i>Blood</i> , 2016, 128, 1018-1018.	1.4	3
69	Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling. <i>Blood</i> , 2016, 128, 3137-3137.	1.4	2
70	Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study. <i>Blood</i> , 2016, 128, 3652-3652.	1.4	2
71	Clinical Application of Massively Parallel Sequencing in the Diagnosis of Hereditary Hemolytic and Dyserythropoietic Anemias. <i>Blood</i> , 2016, 128, 4746-4746.	1.4	2
72	Unravelling Macrophage Heterogeneity in Erythroblastic Islands Between Species. <i>Blood</i> , 2016, 128, 2436-2436.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Reactive Oxygen Species Produced by NADPH Oxidase Contribute to Cardiac Pathology in a Mouse Model of Sickle Cell Disease. <i>Blood</i> , 2016, 128, 853-853.	1.4	0
74	EPO Signaling Triggers Erythrocytosis By Expanding Erythrocytes and Also Subsets of Macrophages. <i>Blood</i> , 2016, 128, 542-542.	1.4	0
75	Treatment of Patients with Severe Congenital Protein C Deficiency in a Registry Study of Protein C Concentrate (Human). <i>Blood</i> , 2016, 128, 2605-2605.	1.4	0
76	Cellular Hydration and Oxidation As Phenotype Modifiers in Sickle Cell Anemia. <i>Blood</i> , 2016, 128, 2446-2446.	1.4	0
77	Cytokinesis failure in RhoA-deficient mouse erythroblasts involves actomyosin and midbody dysregulation and triggers p53 activation. <i>Blood</i> , 2015, 126, 1473-1482.	1.4	26
78	Phylogenetic and Ontogenetic View of Erythroblastic Islands. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	17
79	Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. <i>American Journal of Hematology</i> , 2015, 90, 187-192.	4.1	33
80	Red Blood Cell Dysfunction Induced by High-Fat Diet. <i>Circulation</i> , 2015, 132, 1898-1908.	1.6	71
81	Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 3103-3116.	8.2	62
82	TCD with Transfusions Changing to Hydroxyurea (TWITCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. <i>Blood</i> , 2015, 126, 3-3.	1.4	19
83	Alu-Element Insertion in Pk1r Gene As a Novel Cause of Severe Hereditary Nonspherocytic Hemolytic Anemia. <i>Blood</i> , 2015, 126, 3349-3349.	1.4	1
84	The Spectrum of Alpha-Spectrin Associated Hereditary Spherocytosis. <i>Blood</i> , 2015, 126, 941-941.	1.4	2
85	Genotype-Phenotype Correlations in Hereditary Elliptocytosis (HE) and Hereditary Pyropoikilocytosis (HPP). <i>Blood</i> , 2015, 126, 3344-3344.	1.4	0
86	Activation of HIF-2a-EPO Axis in Kidney or Liver Is Sufficient to Drive Erythrocytosis in a Novel Inducible HIF-2a Transgenic Mouse Model. <i>Blood</i> , 2015, 126, 931-931.	1.4	0
87	Gene Targeting RhoA Reveals Its Essential Role in Coordinating Mitochondrial Function and Thymocyte Development. <i>Journal of Immunology</i> , 2014, 193, 5973-5982.	0.8	37
88	Rho GTPases in erythroid maturation. <i>Current Opinion in Hematology</i> , 2014, 21, 165-171.	2.5	22
89	Identification of a Murine Erythroblast Subpopulation Enriched in Enucleating Events by Multi-spectral Imaging Flow Cytometry. <i>Journal of Visualized Experiments</i> , 2014, , .	0.3	6
90	Effects of Chronic Transfusion Therapy on MRI and MRA in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Imaging from the Twitch Trial. <i>Blood</i> , 2014, 124, 4052-4052.	1.4	7

#	ARTICLE	IF	CITATIONS
91	The Novel PIEZO1 Mutation p.L2023V Is Causal for Hereditary Xerocytosis Resulting in Delayed Channel Inactivation and a Dehydrated Red Blood Cell Phenotype. <i>Blood</i> , 2014, 124, 741-741.	1.4	3
92	Cation Leak in Red Blood Cells of Patients with Wiskott-Aldrich Syndrome Leads to Non-Immunologic Hemolysis. <i>Blood</i> , 2014, 124, 1338-1338.	1.4	0
93	Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. <i>Nature</i> , 2013, 504, 158-162.	27.8	338
94	Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. <i>Blood</i> , 2013, 121, 2099-2107.	1.4	162
95	Signaling and cytoskeletal requirements in erythroblast enucleation. <i>Blood</i> , 2012, 119, 6118-6127.	1.4	114
96	Anchoring at an island to relieve stress. <i>Blood</i> , 2011, 117, 748-749.	1.4	2
97	Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. <i>British Journal of Haematology</i> , 2011, 152, 780-783.	2.5	1
98	Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. <i>Pediatric Blood and Cancer</i> , 2011, 56, 840-842.	1.5	8
99	The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2011, 57, 648-653.	1.5	19
100	K-Cl Cotransporter Gene Expression during Human and Murine Erythroid Differentiation. <i>Journal of Biological Chemistry</i> , 2011, 286, 30492-30503.	3.4	26
101	Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. <i>Haematologica</i> , 2010, 95, 27-35.	3.5	60
102	Rho GTPases in hematopoiesis and hemopathies. <i>Blood</i> , 2010, 115, 936-947.	1.4	142
103	Altered phosphorylation of cytoskeleton proteins in sickle red blood cells: The role of protein kinase C, Rac GTPases, and reactive oxygen species. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 41-45.	1.4	49
104	Rac GTPases in erythroid biology. <i>Transfusion Clinique Et Biologique</i> , 2010, 17, 126-130.	0.4	11
105	Elevated Reactive Oxygen Species Production In Sickle Erythrocytes Is Modulated by a Pathway Involving Endothelin-1, TGF $\beta$ 1, PKC, and Rac GTPases. <i>Blood</i> , 2010, 116, 1634-1634.	1.4	0
106	Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19958-19963.	7.1	49
107	Targeting erythroblast-specific apoptosis in experimental anemia. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2008, 13, 1022-1030.	4.9	14
108	The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. <i>Blood</i> , 2008, 111, 1894-1902.	1.4	45

#	ARTICLE	IF	CITATIONS
109	Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis. <i>Blood</i> , 2007, 110, 3853-3861.	1.4	88
110	Unrestrained erythroblast development in Nix <sup>-/-</sup> mice reveals a mechanism for apoptotic modulation of erythropoiesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 6794-6799.	7.1	129
111	Rac GTPases regulate the morphology and deformability of the erythrocyte cytoskeleton. <i>Blood</i> , 2006, 108, 3637-3645.	1.4	100
112	Pelger-Huet anomaly in a child with 1q42.3-44 deletion. <i>Pediatric Blood and Cancer</i> , 2006, 46, 645-648.	1.5	5
113	A Critical Role for the Retinoblastoma Tumor Suppressor Gene in Hematopoietic Stem Cells. <i>Blood</i> , 2006, 108, 2548-2548.	1.4	1
114	The Voltage-dependent Anion Channel Is a Receptor for Plasminogen Kringle 5 on Human Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 27312-27318.	3.4	86
115	Role of Band 3 Tyrosine Phosphorylation in Causing the Vaso-Occlusive Events in Sickle Cell Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
116	S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS. <i>HemaSphere</i> , 0, 6, 5-5.	2.7	0
117	S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. <i>HemaSphere</i> , 0, 6, 2-2.	2.7	2